摘要
目的评价伏立康唑制剂临床应用的安全性。方法检索中国生物医学文献数据库(CBM)、中国知网(CNKI)的子库《中国医院知识总库》(CHKD)、万方数据库、Cochrane图书馆和Pub Med,截至2014年11月。用Meta Analyst 3.13软件进行统计分析,对各种类型的药物不良反应/不良事件等进行分析。结果共纳入133篇文献,其中包括病例报告34篇。除病例报告外的99个研究中,共有5065人使用伏立康唑。伏立康唑发生药物不良反应/不良事件的主要类型为肝功能损害(13.5%)、视觉损害(7.3%)、消化系统损害(5.1%)、神经系统损害(4.8%)以及皮肤损害(4.3%)等,严重药物不良反应/不良事件率较低。结论伏立康唑的药物不良反应/不良事件发生率主要为肝功能损害、视觉损害、消化系统损害、神经系统损害以及皮肤损害,但转归尚可。严重药物不良反应/不良事件率较低。
Objective To evaluate the safety of clinical application of voriconazole. Methods The systematic literature search was limited to studies with publication dates before November 2014 and included the following databases：Chinese BioMedical Database （CBM）, China Na- tional Knowledge Infrastructure （ CNKI）, Wanfang database, Cochrane Library and PubMed. Meta - analysis was conducted using MetaAnalyst 3.13, as well as the concerned outcomes of various types of adverse reac- tions/events. Results A total of 133 studies, including 34 case reports, were included. Of the 99 studies except the Case reports, 5065 people used voriconazole. Main types of adverse reactions/events were liver function impairment （ 13.5% ）, visual impairment （7.3%）, digestive system impairment （5.1%）, neurological impairment （4. 8% ）, and skin impairment （4. 3% ）, and severe adverse reactions/events were rare. Conclusion Adverse reactions/events of voriconazole are mainly liver impairment, visual impairment, digestive system impairment, neurological impairment and skin impairment, but the outcome is acceptable. Severe adverse reactions/event rates are rare.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2017年第20期2077-2080,共4页
The Chinese Journal of Clinical Pharmacology
关键词
伏立康唑
安全性
系统评价
voriconazole
safety
systematic review
